 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Feb 15, 2024
P1, N=37, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 15, 2024
P1, N=51, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 30, 2023
P1, N=71, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial primary completion date: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Aug 4, 2023
P1, N=37, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial primary completion date: Jun 2023 --> Dec 2023
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Immune cell: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 22, 2023
P2, N=36, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jun 2023 --> Dec 2023 Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 31, 2023
P1, N=51, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 25, 2022
P1, N=71, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Aug 3, 2022
P1, N=37, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment closed, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 9, 2022
P1, N=71, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2022 --> Sep 2022
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment change, Trial completion date, Trial primary completion date: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Apr 7, 2022
P1, N=37, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2022 --> Sep 2022 N=54 --> 37 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 31, 2022
P1, N=88, Recruiting, Sponsor: City of Hope Medical Center
N=54 --> 37 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 31, 2022
P1, N=51, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- CD19 CAR T cells / City of Hope, National Cancer Institute
Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL) (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4481;
P1
This clinical study provides evidence for the safety, feasibility and efficacy of Tn/mem-derived CD19CART preceded by Flu/Cy lymphodepletion for the treatment of r/r B-NHL. We plan to pursue this CAR T cell platform in future B-NHL studies, particularly for CNS lymphoma given the encouraging safety and efficacy of CD19CART in the 5 PCNSL patients.
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Immune cell: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 18, 2021
P2, N=36, Recruiting, Sponsor: City of Hope Medical Center
We plan to pursue this CAR T cell platform in future B-NHL studies, particularly for CNS lymphoma given the encouraging safety and efficacy of CD19CART in the 5 PCNSL patients. Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 15, 2021
P1, N=51, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023 Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment closed: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Apr 8, 2021
P1, N=54, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Recruiting --> Active, not recruiting
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 10, 2021
P1, N=88, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial completion date: Sep 2022 --> Dec 2021 | Trial primary completion date: Sep 2022 --> Dec 2021
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment open, Trial initiation date, CAR T-Cell Therapy, Immune cell: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Dec 17, 2020
P2, N=36, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Sep 2022 --> Dec 2021 | Trial primary completion date: Sep 2022 --> Dec 2021 Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Jan 2021
- | CD19 CAR T cells / City of Hope, National Cancer Institute
New P2 trial, CAR T-Cell Therapy, Immune cell: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 22, 2020
P2, N=36, Not yet recruiting, Sponsor: City of Hope Medical Center
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 25, 2020
P1, N=88, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Jan 2021 Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2022
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 3, 2020
P1, N=88, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2022 Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment change: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 19, 2019
P1, N=88, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021 N=22 --> 88
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 9, 2018
P1, N=22, Recruiting, Sponsor: City of Hope Medical Center
N=22 --> 88 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment change: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 8, 2018
P1, N=22, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 N=48 --> 22
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Apr 23, 2018
P1, N=48, Recruiting, Sponsor: City of Hope Medical Center
N=48 --> 22 Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment open, Trial completion date, Trial primary completion date: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Mar 19, 2018
P1, N=48, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021 Active, not recruiting --> Recruiting | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial completion date, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 14, 2018
P1, N=48, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018 Trial primary completion date: Jan 2018 --> Dec 2018 | Trial completion date: Jan 2018 --> Dec 2018
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial primary completion date: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Aug 3, 2017
P1, N=48, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jan 2018 --> Dec 2018 | Trial completion date: Jan 2018 --> Dec 2018 Trial primary completion date: Sep 2017 --> Sep 2018
- | CD19 CAR T cells / City of Hope, National Cancer Institute
Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 3, 2017
P1, N=48, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Sep 2017 --> Jan 2018
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment closed: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 30, 2017
P1, N=51, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Sep 2017 --> Jan 2018 Recruiting --> Active, not recruiting
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment change: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 15, 2016
P1, N=51, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting N=27 --> 51
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment open: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 11, 2016
P1, N=6, Recruiting, Sponsor: City of Hope Medical Center
N=27 --> 51 Active, not recruiting --> Recruiting
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment closed, Enrollment change: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 15, 2016
P1, N=6, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=24 --> 6
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment closed: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Nov 30, 2015
P1, N=48, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | N=24 --> 6 Recruiting --> Active, not recruiting
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment open: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 6, 2015
P1, N=24, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment closed: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 26, 2015
P1, N=24, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting Suspended --> Active, not recruiting
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment open: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Oct 4, 2014
P1, N=48, Recruiting, Sponsor: City of Hope Medical Center
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment open, Trial primary completion date: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 4, 2014
P1, N=24, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2018 --> Sep 2017
- CD19 CAR T cells / City of Hope, National Cancer Institute
Enrollment open: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 3, 2014
P1, N=24, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2018 --> Sep 2017 Not yet recruiting --> Recruiting
- CD19 CAR T cells / City of Hope, National Cancer Institute
New P1 trial: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov) - Jun 1, 2014
P1, N=48, Not yet recruiting, Sponsor: City of Hope Medical Center
- CD19 CAR T cells / City of Hope, National Cancer Institute
New P1 trial: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 22, 2014
P1, N=24, Not yet recruiting, Sponsor: City of Hope Medical Center
- CD19 CAR T cells / City of Hope, National Cancer Institute
New P1 trial: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 29, 2014
P1, N=24, Not yet recruiting, Sponsor: City of Hope Medical Center